AstraZeneca
NEWS
Tagrisso improved overall survival in lung cancer patients.
Biopharma companies from across the globe share business and development updates.
AstraZeneca and Merck plan on seeking regulatory approval for Lynparza as a treatment for a subset of prostate cancer patients based on the Phase III PROfound data.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to AstraZeneca over its supplemental New Drug Application (sNDA) for Farxiga (dapagliflozin) as an adjunct treatment to insulin for type 1 diabetes (T1D) when insulin alone doesn’t keep blood sugar levels under control.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
During an interim analysis of ELEVATE-TN data, AstraZeneca said Calquence met primary endpoints in patients with previously untreated CLL.
ASCO called rare cancer treatments the “advance of the year” in oncology.
JOBS
IN THE PRESS